Business
Mauna Kea Technologies Announces Results of Its Combined General Meeting of June 5, 2025
PARIS & BOSTON, June 05, 2025--Regulatory News: Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, held its Combined General Meeting of June 5, 2025, which was chaired by Mr. Sacha Loiseau, Chairman of the Board of Directors and CEO.
About this update from Mauna Kea Technologies Sa Class O
[{"type":"text","content":"All the resolutions proposed by the Board of Directors were adopted","length":67,"tagName":"p","attribs":{}},{"type":"text","content":"PARIS & BOSTON, June 05, 2025--(BUSINESS WIRE)--Regulatory News:","length":64,"tagName":"p"},{"type":"text","content":"Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, held its Combined General Meeting of June 5, 2025, which was chaired by Mr. Sacha Loiseau, Chairman of the Board of Directors and CEO.","length":301,"tagName":"p"},{"type":"text","content":"With a quorum of 38.5%, all the resolutions proposed by the Board of Directors have been adopted. Among the main resolutions approved were the adoption of the annual and consolidated financial statements for the year ended December 31, 2024, the allocation of the 2024 net result, as well as delegations granted to the Board of Directors related to financial transactions.","length":372,"tagName":"p"},{"type":"text","content":"Details on the vote results are available on the Company’s website.","length":67,"tagName":"p"},{"type":"text","content":"About Mauna Kea Technologies","length":28,"tagName":"p"},{"type":"text","content":"Mauna Kea Technologies is a global medical device company that manufactures and sells Cellvizio®, the real-time in vivo cellular imaging platform. This technology uniquely delivers in vivo cellular visualization which enables physicians to monitor the progression of disease over time, assess point-in-time reactions as they happen in real time, classify indeterminate areas of concern, and guide surgical interventions. The Cellvizio® platform is used globally across a wide range of medical specialties and is making a transformative change in the way physicians diagnose and treat patients. For more information, visit www.maunakeatech.com.","length":643,"tagName":"p"},{"type":"text","content":"Disclaimer","length":10,"tagName":"p"},{"type":"text","content":"This press release contains forward-looking statements about Mauna Kea Technologies and its business. All statements other than statements of historical fact included in this press release, including, but not limited to, statements regarding Mauna Kea Technologies' financial condition, business, strategies, plans and objectives for future operations are fo...